Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed)
Key details
- Offered by
- National Institutes of Health
- Type
- Funding opportunity
- Funding type
- Grant
- Amount
- $250,000
- Posted
- October 15, 2024
- Closes
- October 14, 2026
- Last verified
- September 22, 2026
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This NOFO will also support the validation of pharmacodynamic markers and markers of toxicity. Applicants to this NOFO must have an assay(s) whose performance has been analytically validated in specimens similar to those for the intended clinical use of the marker(s) and assay(s). As chemotherapies and/or radiation therapies are increasingly combined with immunotherapies to enhance the durability of anti-cancer responses, assays for measuring multiple markers, including immune markers, can be developed and validated simultaneously. The UH3 mechanism will support the clinical validation of established assays for up to 3 years using specimens from retrospective or prospective clinical trials or studies. This NOFO may be used to validate existing assays for use in other trials, observational studies, or population studies. Efforts to harmonize clinical laboratory tests, including investigation into the performance and reproducibility of assays across multiple clinical laboratories, are also appropriate for this funding opportunity. Projects proposed for this NOFO will require multi-disciplinary interaction and collaboration among scientific investigators, oncologists, statisticians, and clinical laboratory scientists. This NOFO is not intended to support early-stage development of technology or the conduct of clinical trials but is intended for validation of assays to the point where they could be integrated into clinical trials/studies as investigational assays.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Apply on the official page
You apply directly with the organization offering this. They make the final eligibility and award decision.
Get help with your application
Create a free account to save this, track deadlines, and build your application with our writing tools.
Related groups
Other open opportunities like this
- Funding opportunityGrant
BJA FY 2026 Harold Rogers Prescription Drug Monitoring Program
Bureau of Justice Assistance
This is a notice of funding opportunity (NOFO) for the BJA FY2026 Harold Rogers Prescription Drug Monitoring Program (PDMP). This opportunity seeks to enhance the capacity of regulatory and law enforcement agencies and public health officials to collect and analyze controlled substance prescription data and other scheduled chemical products through a centralized database administered by an authorized agency. PDMPs help state and local governments to detect and prevent the diversion and abuse of pharmaceutically controlled substances such as opioids and other prescription drugs. The primary function of a PDMP is to facilitate the collection, analysis, and reporting of information on the prescribing, dispensing, and use of prescription drugs with a state, commonwealth, district, or territory. The goal of the Harold Rogers PDMP is to strengthen states’ and territories’ ability to maintain and enhance their existing PDMPs by accommodating local decision-making based on state laws and preferences and replicating promising practices. As part of supporting the enhancement of PDMPs, the Harold Rogers PDMP supports the integration of PDMP data with health information exchanges, electronic health records, or pharmacy dispensing systems, including engaging with tribal entities and rural areas where integration rates may be lower. This program helps to break the cycle of drug addiction and violence by reducing the demand, use, and the illegal trafficking of controlled substances.
- Amount:
- $0 to $2,000,000
- Closes:
- Sep 23, 2026
- Funding opportunityGrant
FY27 Brownfields Job Training (JT) Grants
Environmental Protection Agency
This notice announces the availability of funds and solicits applications from eligible entities to deliver Brownfields Job Training programs that recruit, train, and place local, unemployed, and underemployed residents with the skills needed to secure full-time employment in the environmental field. Brownfields Job Training Grants fund training programs that strengthen local workforces by preparing program graduates for environmental jobs that support cleanup and revitalization efforts in their own communities. Training may include a range of brownfield-related environmental skills such as the assessment and cleanup of solid and hazardous waste; chemical risk management; stormwater management relating to site cleanup; planning and site preparation for low-impact development activities; site preparation for green infrastructure installation; and vulnerability assessment and contamination mitigation planning. Please carefully review Section 4.E. of these guidelines, Section IV of EPA NOFO Clauses, and the Frequently Asked Questions, which can be found at https://www.epa.gov/brownfields/frequently-asked-questions-about-brownfields-job-training-jt-grants. A checklist of required application forms and documents is in Section 4.A. For the purposes of these guidelines, the term “grant” refers to the cooperative agreement that EPA will award to a successful applicant. In this Notice of Funding Opportunity (NOFO), “Project” refers to the applicant’s proposed Brownfields Job Training effort to be funded under this competition. Unless otherwise noted, “training program” is used synonymously with “project.”
- Amount:
- $300,000
- Closes:
- Sep 23, 2026
- Funding opportunityGrant
BJA FY26 Investigating and Prosecuting Sexual Assaults in Confinement Facilities Program
Bureau of Justice Assistance
This is a notice of funding opportunity (NOFO) for the BJA FY 2026 Investigating and Prosecuting Sexual Assaults in Confinement Facilities Program. This opportunity supports state, local, and tribal efforts to enhance their capacity to investigate and prosecute incidents of sexual assault in confinement facilities. State agencies, law enforcement, and prosecutorial agencies may utilize this funding for investigative and prosecutorial activities to decrease incidents of sexual assault in confinement facilities and increase the rate of successful prosecutions in such cases.
- Amount:
- $0 to $2,000,000
- Closes:
- Sep 23, 2026
- Funding opportunityGrant
BJA FY 2026 Intellectual Property Enforcement Program: Protecting Public Health, Safety, and the Economy from Counterfeit Goods and Product Piracy
Bureau of Justice Assistance
This is a notice of funding opportunity (NOFO) for the BJA FY2026 Intellectual Property Enforcement Program: Protecting Public Health, Safety, and the Economy from Counterfeit Goods and Product Piracy. This opportunity will support existing or the creation of new law enforcement agency intellectual property (IP) enforcement task forces. This program assists state, local, tribal, and territorial jurisdictions in preventing and reducing intellectual property theft and related crime as well as supporting law enforcement in investigating and prosecuting IP crimes and reducing violent crime associated with IP cases and investigations. These matters typically involve copyrights, patents, trademarks, other forms of IP, and trade secrets, both in the United States and abroad.
- Amount:
- $0 to $375,000
- Closes:
- Sep 23, 2026
- Funding opportunityGrant
BJA FY 2026 Edward Byrne Memorial Justice Assistance Grant (JAG) Program—State Formula
Bureau of Justice Assistance
The Office of Justice Programs (OJP) is committed to advancing work that furthers the U.S. Department of Justice’s (DOJ) mission to keep our country safe and secure and uphold the rule of law and protect the rights of American citizens. OJP provides federal leadership, funding, and other critical resources to directly support law enforcement, combat violent crime, protect American children, provide services to American crime victims, and address public safety challenges, including human trafficking and the opioid crisis. This is a notice of funding opportunity (NOFO) for the BJA FY2026 Edward Byrne Memorial Justice Assistance Grant (JAG) Program—State Formula. This opportunity will provide formula funding to states to, in general, support hiring additional personnel and/or purchase equipment, supplies, contractual support, training, technical assistance, and information systems for criminal justice or civil proceedings, including for any one or more of the eleven program areas. With this Notice of Funding Opportunity (NOFO), BJA seeks to award Edward Byrne Memorial Justice Assistance Grant (JAG) Program funds to eligible states. Only designated state administering agencies are eligible to apply for this NOFO.
- Amount:
- $0 to $21,479,876
- Closes:
- Sep 23, 2026
- Funding opportunityGrant
DoW Alzheimer’s Transforming Research Award
Defense Health Agency Contracting Activity - DHACA
Summary: The fiscal year 2026 (FY26) Alzheimer’s Research Program (AZRP) Transforming Research Award (TrRA) supports non-incremental, robust, well-designed research that drives transformative advancements in reducing risk and preventing the development of Alzheimer’s disease and/or Alzheimer's disease related dementias (AD/ADRD). Distinctive Features: • Applications must address at least one of the following focus areas: ○ Risk Factor Knowledge: Research that advances understanding, identification, and/or validation of risk and/or protective factors, with research outcomes/products focused on accelerating solutions. Projects may include, but are not limited to, research on environmental, epigenetic, genetic, lifestyle, occupational, or other risks not listed here. ○ Risk Reduction Solutions: Research that describes methods, technologies, and strategies that contribute to reducing risk and preventing AD/ADRD. • Clinical research is allowed, however clinical trials and animal research are prohibited. • Preliminary data are required. • Community collaboration is required for research prospectively enrolling human subjects. • Career Initiation or Transition (CIT) Partnership Option: The TrRA includes an option for more than one PI and supports both new and existing collaborative partnerships. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). If utilizing this option, at least one independent investigator must meet
- Closes:
- Sep 24, 2026